Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease

Alpha Cognition has made a significant step forward in Alzheimer’s research by enrolling the first patient in its RESOLVE Phase 4 study for ZUNVEYL®, a drug aimed at treating mild to moderate Alzheimer’s disease. This study aims to gather more data on the drug's safety and effectiveness after it has been marketed. This development is crucial because it seeks to provide more comprehensive insights into how well ZUNVEYL® works in real-world settings, potentially influencing future treatment protocols and patient care strategies.